This review compared the results of studies assessing low or high intensities of vitamin K antagonists (VKA) in patients with mechanical aortic and mitral heart valves. The authors concluded that high-intensity VKA was preferable. There were limitations to the quality of the review and the included studies, and the conclusions should therefore be treated with caution.
Data extraction
Two reviewers extracted the data independently, with any disagreements resolved by consensus. Where prothrombin times were used as treatment targets, these were converted to an INR. Treatment was classified as high-intensity VKA where the mean target INR was above 3.0, and low-intensity VKA where the mean target INR was 3.0 or lower. For each outcome in each study, the annual incidence rate (number of outcome events divided by number of patient-years) and standard error were calculated. Where no events occurred a nominal 0.5 was added in the calculations.
Methods of synthesis
How were the studies combined? Average incidences for each event across studies were calculated by adding the yearly incidence rates of all studies and dividing by the number of studies. Risk ratios (RR) and 95% confidence intervals (CIs) were calculated assuming a Poisson distribution of the data. Statistically significant differences between incidences in different groups were investigated using a Wald test, with a P-value of less than 0.05 taken to be statistically significant.
How were differences between studies investigated?
Results for mitral valve prostheses were analysed separately to those for aortic prostheses. Other than this, the authors did not state a method for assessing differences between the studies.
Results of the review
Thirty-five studies (23,145 participants) were included in the review.
Aortic valves.
There were less valve thrombosis events in the high-intensity VKA group than in the low-intensity group: 0.87 versus 1.16 per 1,000 patient-years (RR 0.75, 95% CI: 0.50, 1.13, P=0.126). There were less thromboembolisms in the highintensity group than in the low-intensity group: 9.83 versus 13.09 per 1,000 patient-years (RR 0.75, 95% CI: 0.70, 0.81, P<0.0001). The total number of thromboembolic events was less in the high-intensity group than in the low-intensity group: 10.01 versus 13.69 per 1,000 patient-years (RR 0.73, 95% CI: 0.68, 0.78, P<0.0001). There was an increase in bleeding events in the high-intensity group compared with the low-intensity group: 14.89 versus 12.06 per 1,000 patientyears (RR=1.23, 95% CI: 1.16, 1.31, P<0.0001).
When all embolic and haemorrhagic events were combined, there was a reduction in the total number of all events in the high-intensity group compared with the low-intensity group: 23.84 versus 25.39 per 1,000 patient-years (RR 0.94, 95% CI: 0.88, 0.99, P=0.0067).
Mitral valves.
Patients in the high-intensity VKA group had a lower risk of valve thrombosis and thromboembolism than those in the low-intensity group: 2.06 versus 3.44 per 1,000 patient-years for valve thrombosis (RR 0.60, 95% CI: 0.47, 0.76 P<0.0001), and 15.91 versus 20.12 per 1,000 patient-years for thromboembolism (RR 0.79, 95% CI: 0.74, 0.84, P<0.0001). Bleeding events did not differ significantly between high-and low-intensity VKA: 12.94 versus 11.96 per 1,000 patient-years (RR 1.08, 95% CI: 1.00, 1.116, P=0.0524). The total number of events was 29.76 per 1,000 patientyears in the high-intensity group and 35.33 per 1,000 patient-years in the low-intensity group (RR 0.84, 95% CI: 0.79, 0.89, P<0.001).
Comparison between mitral and aortic prostheses.
The number of valve thrombosis and thromboembolic events was significantly lower in the aortic valve group than in the mitral valve group for both high-and low-intensity VKA. For high-intensity VKA, patients with aortic prostheses were more likely to haemorrhage than those with mitral prostheses (RR 1.15, 95% CI: 1.06, 1.25). However, there was no difference in bleeding complications for low-intensity VKA (RR 1.01, 95% CI: 0.94, 1.07).
